FDA Oncology Announcements

PARP inhibitor × Gynecologic × Clear all

6 Announcements

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers

Trial: DUO-O
Drugs: LYNPARZA (olaparib) · PARP inhibitor, bevacizumab · Anti-VEGFR antibody
Condition: Gynecologic

FDA approves niraparib for first-line maintenance of advanced ovarian cancer

Drug: ZEJULA (niraparib) · PARP inhibitor
Condition: Gynecologic

FDA approves niraparib for HRD-positive advanced ovarian cancer

Trial: QUADRA
Drug: ZEJULA (niraparib) · PARP inhibitor
Condition: Gynecologic

FDA approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals LP) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based

Trial: SOLO-1
Drug: LYNPARZA (olaparib) · PARP inhibitor
Condition: Gynecologic

FDA approves rucaparib for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer

Trial: ARIEL3
Drug: Rubraca (rucaparib) · PARP inhibitor
Condition: Gynecologic

FDA approves olaparib tablets for maintenance treatment in ovarian cancer

Drug: Lynparza (olaparib) · PARP inhibitor
Condition: Gynecologic